Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neoplasms

• A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
• A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
• Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
• S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
• Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
• A Study of LM-24C5 For Advanced Solid Tumors
• A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
• CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
• A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
• Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
• Study of AZD9829 in CD123+ Hematological Malignancies
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
• A Study of JNJ-87890387 for Advanced Solid Tumors
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
• Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
• Phase I Study of ANK-101 in Advanced Solid Tumors
• A Study of ASP1012 in Adults With Solid Tumors
• MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
• SG2918 For Advanced Malignant Tumors
• Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
• A Study of AK131 in Patients With Advanced Solid Tumors
• a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
• A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
• A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
• A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
• A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
• Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC
• A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
• A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
• A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
• A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy
• A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
• FIH XON7 in Advanced/Metastatic Solid Tumors
• MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
• A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
• Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
• GT201 Injection For The Treatment Of Advanced Solid Tumors
• Study of TRX-920 for Patients With Advanced Solid Tumors
• A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
• A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
• Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
• AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
• First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
• Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
• A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
• A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
• Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
• A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours
• Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
• Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion.
• A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
• Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
• A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
• Precision Cancer Therapy in Rare Cancers
• A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
• A Study of WX390 in Patients With Advanced Solid Tumors
• Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
• A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
• Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
• The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
• Study of DF6215 in Patients With Advanced Solid Tumors
• JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
• A Study of YL202 in Selected Patients With Advanced Solid Tumors
• A Study of Avutometinib for People With Solid Tumor Cancers
• A Study of DCR-STAT3 in Adults With Solid Tumors
• Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
• A Study of HY-0102 in Patients With Advanced Solid Tumors
• An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
• Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
• A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
• UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
• Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
• Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
• Clinical Study of SM3321 With Solid Tumors
• Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
• Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
• Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
• Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
• A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients
• A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients
• The Efficacy and Safety of IBI363 in Solid Tumors.
• The Application of Novel Oncolytic Virus in Late Stage Solid Tumors
• Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
• A Study of YL-17231 in Patients With Advanced Solid Tumors
• PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
• An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
• Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
• A Study of DS-1471a In Subjects With Advanced Solid Tumors
• A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors
• Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
• PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
• A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
• A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
• Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
• Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
• CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
• A Study YL201 in Patients With Selected Advanced Solid Tumors
• A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
• A Study of HB0045 Injection in Patients With Advanced Solid Tumors
• Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
• A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis
• CD34 Selection Using the Automated CliniMACS Prodigy
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
• A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
• A Study of ADRX-0706 in Select Advanced Solid Tumors
• CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
• Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
• Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
• A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
• Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
• A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
• A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
• A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
• Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
• Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
• Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
• A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
• Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
• A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
• Multicenter Trial of ESK981 in Patients With Select Solid Tumors
• Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors
• A Study Of IMM47 In Subjects With Advanced Solid Tumors
• A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
• Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
• An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
• A Phase I/II Clinical Study in Patients With Advanced Solid Tumor.
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
• Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
• HTL0039732 in Participants With Advanced Solid Tumours
• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
• Online Tai Chi Intervention to Promote Smoking Cessation Among Cancer Survivors
• A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
• RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
• A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
• Study of LP-184 in Patients With Advanced Solid Tumors
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
• Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
• A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
• Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
• Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
• Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
• Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
• A Study of BA1202 in Patients With Advanced Solid Tumors
• Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
• A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
• A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
• Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
• AMT-253 in Patients With Selected Advanced Solid Tumours
• SKB410 for Injection in Solid Tumors
• KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
• Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
• Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
• A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
• Safety and Tolerability of Intravenous Administration of ICVB-1042
• RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
• A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
• Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
• Phase I Study of EOC237 in Patients With Advanced Solid Tumor
• HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors
• TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
• A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
• Clinical Study of Weifuchun Treatment on Gastric Cancer
• 68Ga-P3 PET/CT Imaging in Malignancy
• Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
• Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
• A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
• Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
• NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
• A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
• To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
• A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
• A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
• Study of ZG0895.HCl in Patients With Advanced Solid Tumors
• Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
• First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
• Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
• BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
• A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors
• Clinical Trial Evaluating the Safety of the TQB2103 for Injection
• Study of ARTS-021 in Patients With Advanced Solid Tumors
• A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
• To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
• Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
• A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
• Tolerability and Safety of HF158K1 Injection in Participants With HER-2 Positive or Low Expression Advanced Solid Tumors
• Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
• A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
• SG1906 for CLDN18.2-Positive Solid Tumors
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
• Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
• Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
• Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
• 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
• Phase 2 Trial Comparing the Safety and Efficacy of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
• CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.
• Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
• Clinical Trial of PM54 in Advance Solid Tumors Patients.
• Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
• Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)
• Study of GS-4528 in Adults With Solid Tumors
• A Study of IMC008 for Advanced Solid Tumors
• The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
• A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
• A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
• PM534 Administered Intravenously to Patients With Advanced Solid Tumors
• Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
• Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.
• IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
• A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
• A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
• First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
• A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
• A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
• Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors
• A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
• Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
• A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
• A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
• JYB1907 in Subjects With Advanced Solid Tumors
• A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors
• Comparaison Between Digital and Drug Induced Sedation in Veinous Access Device Implantation
• First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
• PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer
• KSX01-TCRT Injection Project in Solid Tumors
• A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
• Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
• Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Therapy of Metastatic or Recurrent Solid Tumors With BRCA Mutations
• A Study of KM501 in Patients With Solid Tumors
• Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
• A Clinical Study of BL-B01D1 in Patients With Multiple Solid Tumors Such as Recurrent or Metastatic Gynecological Malignancies
• Aldesleukin in Combination With Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer With Peritoneal Metastasis, CONTROL Study
• PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
• A Phase I Study of QL1604 for Advanced Solid Tumors
• PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
• Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
• Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
• A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
• A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
• An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
• AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
• Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
• Phase 1 Study of BPI-460372 in Advanced Solid Tumor Patients
• A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
• A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers
• DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
• DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
• A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors
• Phase II Clinical Study of BL-B01D1 in Patients With Multiple Solid Tumors Such as Locally Advanced or Metastatic Urinary System Tumors
• Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors
• A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
• A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
• A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
• Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
• IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
• A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
• A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
• Avatrombopag vs. Placebo for CIT in GI Malignancies
• A Study of XZB-0004 in Patients With Solid Tumors
• DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
• DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficie
• DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
• A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
• BAL0891 in Patients With Advanced Solid Tumors
• A Phase 1 Study to GEC255 Oral Tablets in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
• Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia
• DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
• Neoantigen Derived DCs as Cancer Treatment
• BAT7104 Injection in Patients With Advanced Malignant Tumors.
• A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
• Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
• A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
• A Phase 1a/1b First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors
• Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
• First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
• A Study of HS248 in Patients With Advanced Solid Tumors
• Oxygen Atomizing Inhalation of EGCG in the Treatment COVID-19 Pneumonia in Cancer Patients
• Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
• Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
• Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
• TR128 in Patients With Advanced Solid Tumors
• Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors
• Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
• A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
• Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
• A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
• To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
• Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
• A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
• A Phase 1/2 of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
• Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
• A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
• A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
• Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
• The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
• Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
• A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
• The Study of ICP-248 in Patients With Mature B-cell Malignancies
• Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
• Evaluate the Safety, Tolerability, Dose-finding and Expansion of Intratumoral Injection of JCXH-211 Injection
• Fluid Challenge and Plasma Volume, During Surgery
• AMT-116 in Patients With Selected Advanced Solid Tumors
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
• Phase 1 Study of PYX-201 in Solid Tumors
• A Study of ASP1002 in Adults for Treatment of Solid Tumors
• A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
• Phase 1 Study of PYX-106 in Solid Tumors
• Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors
• Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)
• A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
• A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
• CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
• Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
• A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
• Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
• Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
• A Study of HB0030 Injection in Patients With Advanced Solid Tumors
• A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
• Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
• A Phase 1 Study of EBC-129 in Advanced Solid Tumours
• Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
• IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
• Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
• CD40 Ligand Expressing MSLN-CAR T Cell Therapy in MSLN Positive Advanced/Metastatic Solid Tumors
• Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
• Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
• Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors
• Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
• A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
• Tranexamic Acid During Upper GI Endoscopic Resection Procedures
• Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
• XTX301 in Patients With Advanced Solid Tumors
• A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
• HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
• Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
• Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
• A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
• A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
• Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
• TT-00973-MS Tablets in Patients With Advanced Solid Tumors
• A Phase 1/2a, Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
• Transarterial Chemoembolization for the Treatment of Lung Cancer
• Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
• A Study of GV20-0251 in Patients With Solid Tumor Malignancies
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
• A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
• Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
• Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
• NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
• Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
• Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
• A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions
• Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
• Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
• A Study of AK130 in Patients With Advanced Malignant Tumors
• Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
• DECOY20 Study in Patients With Advanced Solid Tumors
• A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
• A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
• A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies
• A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
• TIL Cells for the Treatment of the Advanced Solid Tumors Patients
• TR64 in Patients With Advanced Solid Tumors
• TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
• A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
• A Study of ASP2074 in Adults With Solid Tumors
• Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
• Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
• A Study of AK129 in Patients With Advanced Malignant Tumors
• Safety, Pharmacokinetics and Antitumor Activity of BGB-B167alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
• Phase I/2 Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
• SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
• Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
• A Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
• A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
• A Study of RD14-01 in Patients With Advanced Solid Tumors
• Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
• Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
• Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial
• Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
• A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
• Phase II of CD30 CAR for CD30+ NSGCT
• Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
• Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
• Combination of CAR-DC Vaccine and PD-1 Antibody in Local Advanced/Metastatic Solid Tumors
• JZP341 Phase 1 Dose-Finding Study in Adult Participants With Advanced or Metastatic Solid Tumors
• SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
• A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
• A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
• SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
• First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
• A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
• A Prospective, Open-label, Multi Cohort Clinical Study on the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With Camrelizumab Combined With Chemotherapy
• Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors
• Phase I Study of the BBP-398 in Chinse Patients With Advance Solid Tumors
• A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
• A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
• A Study of LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3
• Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
• A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Part
• A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors
• Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
• RP-6306 in Patients With Advanced Cancer
• A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies
• Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors Solid Tumors
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Excess Blasts
• Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced
• Hyperpolarized 13C Pyruvate as a Biomarker in Advanced Solid Tumors
• Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
• Study of DF9001 in Patients With Advanced Solid Tumors
• A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
• 68Ga-N188 PET/CT Imaging in Malignancy
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
• Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
• Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
• A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
• Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
• Oral Administration of STC-15 in Subjects With Advanced Malignancies
• Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
• DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are L
• A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
• Intratumoral CAN1012 in Subjects With Solid Tumors
• KSH01-R02-101 Solid Tumors
• Mirdametinib + BGB-3245 in Advanced Solid Tumors
• A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
• Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
• A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
• Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
• Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy
• A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma.
• Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
• Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
• A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
• A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Registration Trial
• A Phase 1a/1b FIH Study of PY265 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
• Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
• Study of Chemotherapy Plus Ipatasertib in Participants With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
• Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
• Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
• Prevalence of Marginal Ulcer After PPPD and Preventive Effect of Proton Pump Inhibitor in Korea: A Prospective Multicenter Study
• A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
• Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
• Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.
• A Phase 1/2 Study of Oral MRT-2359 in Selected Cancer Patients
• Study of SGR-1505 in Mature B-Cell Neoplasms
• To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
• KSH01-TCRT Solid Tumors
• Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
• A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
• Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
• Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose
• Phase I Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
• Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
• Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
• Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
• PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
• Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
• A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
• Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
• SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
• A Study in Patients With Advanced Cancers
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
• 6MW3511 in Patients With Advanced Solid Tumor
• Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
• SB17170 Phase 1 Clinical Trial in Solid Tumors
• Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
• FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors
• Erector Spinae Block for Thoracic Surgery
• Olverembatinib for FGFR1-rearranged Neoplasms
• Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
• A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
• Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
• A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
• Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
• Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
• A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors
• A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
• A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
• Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
• Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
• A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
• A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
• A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
• Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
• A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
• DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
• First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
• JSKN003-101 First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
• Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
• 68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
• Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
• A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
• Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
• A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
• Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
• SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
• Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors
• Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
• A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors
• Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
• Subjects With Advanced or Metastatic Solid Tumor Malignancies
• Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
• Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
• A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
• A PhaseⅠ Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
• A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)
• An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
• Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
• Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
• A Study of HR19024 in Subjects With Advanced Solid Tumor
• Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
• A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
• A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
• Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
• Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
• CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
• Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• HEC169096 in Participants With Advanced Solid Tumors
• 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
• A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
• A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors
• Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
• Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
• First-in-human Study of DB-1303 for Advanced/Metastatic Solid Tumors
• Phase II Study of Reduced MBF Regimen for Patients Over 50 Years With Myeloid Malignancies
• CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
• A Study of YL201 in Patients With Advanced Solid Tumors
• A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
• A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
• A Phase I Clinical Study of JS004 Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
• A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
• Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
• A Study of TRK-950 in Patients With Advanced Solid Tumors
• Study on TIL for the Treatment of Advanced Malignant Solid Tumors
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
• A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
• A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
• Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
• To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors
• A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
• Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
• 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
• ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
• Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
• Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
• Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 in Combination With HLX10 in Patients With Advanced/Metastatic Solid Tumor
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
• A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
• Psilocybin Therapy in Advanced Cancer
• Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
• Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening
• A Phase I/IIa Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
• A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
• The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
• A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
• Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
• A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
• A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
• Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
• Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
• A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
• A Study of KL340399 in Patients With Advanced Solid Tumors
• A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
• Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
• A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
• Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
• Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors
• A Study of ASP3082 in Adults With Previously Treated Solid Tumors
• A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
• Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors
• Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
• Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
• A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
• A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors
• Study of AGEN1571 in Participants With Advanced Solid Tumors
• Study of VS-6766 + Adagrasib in KRAS G12C NSCLC Patients
• A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma and Other Solid Tumors
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
• A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
• Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
• A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
• A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
• Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors
• A Phase 1 Clinical Study of SKB315 in Patients With Advanced Solid Tumors
• A Study of ICP-033 in Patients With Advanced Solid Tumors
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations
• Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
• HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
• A Study to Measure How a New Method for Dosing Vincristine in Infants and Young Children Compares to the Standard Dosing Method in Older Children
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
• Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo
• Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
• Phase I Clinical Study of BR105 Injection
• Nirogacestat in Ovarian Granulosa Cell Tumors
• A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
• A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors
• Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery
• A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
• Study of PAT in Patients With Solid Tumor Cancers
• A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
• A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)
• Phase II Study of Salvage Radiation Treatment (RT) After B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-cell Therapy (CAR-T) for Relapsed Refractory Multiple Myeloma
• Lopinavir/Ritonavir in PLWH With High-Grade AIN
• Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
• A Safety and Efficacy Study of Domvanalimab + Zimberelimab Combination Therapy in Participants With Advanced Upper Gastrointestinal Tract Malignancies
• An Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
• Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors
• A Study of WJ05129 in Advanced Malignant Solid Tumors
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
• Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors
• Phase I HCW9218 in Select Advanced Solid Tumors
• Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
• A Phase 1/2 Study in Patients With Advanced Cancers
• A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
• A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors
• Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
• Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
• A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
• A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
• Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
• HBM7008 -Study on Subjects With Advanced Solid Tumors
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
• Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
• Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
• Treatment of Chinese Patients With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader
• SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
• A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
• Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
• Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
• Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
• Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
• RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors
• Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
• Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
• Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
• FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
• A Study of QLS31905 in Patients With Advanced Solid Tumors
• A Study of ILB2109 in Patients With Advanced Solid Malignancies
• Tirelizumab Combined With Cetuximab and Irinotecan vs Third-line Regimens in the Treatment of Refractory mCRC
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
• Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
• ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
• A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
• A Study of the HS-20093 in Patients With Advanced Solid Tumors
• Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
• Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
• An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
• TT-702 in Patients With Advanced Solid Tumours.
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
• A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
• A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
• A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Subjects With Advanced Malignant Solid Tumors
• A Study of KL590586 in Patients With Advanced Solid Tumors
• The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
• A Study of CM350 in Patients With Advanced Solid Tumors
• A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
• A Study of HS-20089 in Patients With Advanced Solid Tumors
• A Study Explore JS001+IMP4297 in Patients With Advanced Cancer
• A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
• A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors
• Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
• CXCR4-targeted PET/CT Imaging in Hematological Malignancies
• Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
• A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
• A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
• Anrotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
• 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
• Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
• A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
• Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Tria
• Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
• IBI397 or Its Combination Therapies in Patients With Advanced Malignancies
• Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
• SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
• FGFR2/3 Inhibitor ABSK061 in Patients With Advanced Solid Tumors Phase I Study
• Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
• A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors
• Study of INCB123667 in Subjects With Advanced Solid Tumors
• SMMART Adaptive Clinical Treatment (ACT) Trial
• A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
• Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
• Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors
• A Study of SGN-ALPV in Advanced Solid Tumors
• A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
• YL-13027 in Patients With Advanced Solid Tumors
• Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
• Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms
• Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
• Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer
• 18F F-AraG-PET Imaging to Evaluate Immunological Response CKI Therapy in Solid Tumors Imaging
• A First-in-human of Multiplle Doses of BB-1701 in Subjects With Locally Advanced/Metastatic Solid Tumors
• A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
• A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
• A Study of AK112 in Advanced Malignant Tumors
• Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
• Study of FCN-098 in Patients With Advanced Solid Tumor
• An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
• Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Young Adults
• A Study of SHR-1802 in Patients With Advanced Solid Tumor
• Phase 1 Study of the HS-10365 in Patients With Advanced Solid Tumors
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
• A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
• Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
• Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
• Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
• A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
• A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
• AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
• A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
• A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
• Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
• First in Human Study of M1069 in Advanced Solid Tumors
• MAX-10181 in Patients With Advanced Solid Tumor
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
• A Study of SGN-B7H4V in Advanced Solid Tumors
• A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
• Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
• Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
• Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
• Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
• Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
• A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
• Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer
• Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors
• Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
• Selinexor Combination Ph 1 Study
• Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
• EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
• A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors
• Nivolumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
• A Study of FDA018-ADC in Patients With Advanced Solid Tumors
• A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
• Study of AK119 in Subjects With Advanced Solid Tumors
• HMPL-453 Tartrate Combined With Chemotherapy or Teriprizumab in Patients With Advanced Solid Tumors
• A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
• PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
• A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
• A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
• Vaccine Responses in Patients With B Cell Malignancies
• Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
• A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors.
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
• HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
• An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
• A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
• Safety and Efficacy of IBI389 Single Agent and in Combination With Sintilimab in Patients With Advanced Malignancies
• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
• S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
• Study of LM-302 in Patients With Advance Solid Tumors
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
• A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
• A Study of PRT2527 in Patients With Advanced Solid Tumors
• A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
• Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
• A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors).
• Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
• Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
• A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
• Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
• Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
• A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure
• A Study of DB-1303 in Advanced/Metastatic Solid Tumors
• Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
• A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
• 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION)
• A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
• A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
• Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
• A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
• A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study
• Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
• Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
• Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors
• A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors
• Therapeutic Dose Monitoring (TDM) of Tamoxifen
• A Phase 1 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
• A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
• A Study of ZN-c3 in Subjects With Malignant Tumors
• A Study Explore JS001+JS002 in Patients With Advanced Cancer
• A Study of NDI 1150-101 in Patients With Solid Tumors
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
• Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
• A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
• An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
• Local Anesthesia Versus Combined Local Anesthesia With Single Dose Analgesia on Pain Control During Thoracic Ultrasound Guided Procedures
• A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
• A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
• Sacituzumab Govitecan in Patients With Solid Tumor
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
• Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
• A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
• A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
• Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors
• Off-the-shelf NK Cells + SCT for Myeloid Malignancies
• ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
• A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors
• A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
• Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
• Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
• A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
• QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
• A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
• A Study of NX-1607 in Adults With Advanced Malignancies
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
• A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
• Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)
• Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
• First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
• The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
• Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
• S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
• Clinical Trial of WB100 on Advanced Solid Tumor
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
• First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
• Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients
• Effect(s) of Esketamine Combined With Pregabalin on Postsurgical Pain in Spinal Cord Neoplasms Patients
• A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor
• AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
• A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
• Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors
• A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
• A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
• A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
• ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
• A Study of ASP1570 in Adults With Advanced Solid Tumors
• A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
• Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
• Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection
• IL Believe: A Study of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
• IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
• A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
• PM14 Administered Intravenously to Patients With Advanced Solid Tumors
• Intensity Modulated Proton Therapy After Surgery for the Treatment of Head and Neck Cancer, the HEADLIGHT Study
• A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
• Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
• Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
• A Study of SKLB1028 in Patients With Advanced Solid Tumor
• Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
• Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
• FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
• Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
• A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
• A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001)
• Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
• A Study of ZL-1211 in Patients With Advanced Solid Tumor
• Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
• A Study of of HOT1030 in Patients With Advanced Solid Tumors
• Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
• Study of Vimseltinib for Tenosynovial Giant Cell Tumor
• A Study of HS269 in Patients With Advanced Solid Tumors
• Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
• Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
• APL-102 Capsule in Patients With Advanced Solid Tumors
• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
• XTX202 in Patients With Advanced Solid Tumors
• Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
• A Study of GFH018 in Patients With Advanced Solid Tumors
• A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
• A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
• A Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies in Patients Undergoing Routine Surgery
• KZR-261 in Subjects With Advanced Solid Malignancies
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
• A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
• Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
• ARX788 in Selected HER2-mutated or HER2-amplified Solid Tumors (ACE-Pan Tumor-02)
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
• A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
• Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
• Phase I Study of SGN1 in Patients With Advanced Solid Tumor
• Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
• Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
• A Study of NB004 in Patients With Advanced Solid Tumors
• 68Ga-FAPI PET/CT in Malignant Tumors
• Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
• Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
• Phase 1 Study of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
• A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
• A Clinical Study of TQB3824 in Subjects With Advanced Cancer
• Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
• Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.
• Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
• NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
• Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
• A Study of TQB3820 in Patients With Hematological Malignancies
• A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
• A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
• A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
• To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
• Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
• A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
• Milademetan in Advanced/Metastatic Solid Tumors
• Dose Finding Study of GH35 in Patients With Advanced Solid Tumors
• A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
• BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
• Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
• FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China
• Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
• A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
• Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
• Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
• A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
• PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
• JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
• Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
• Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
• A Study of HG381 Administered to Patients With Advanced Solid Tumors
• Leflunomide in Patients With PTEN-null Advanced Solid Malignancies
• (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
• ALPPS Combined With Tislelizumab in Liver Malignancy
• A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
• A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
• Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors
• Study of INCA 0186 in Subjects With Advanced Solid Tumors
• Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors
• Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
• Intratumoral CAN1012 in Subjects With Solid Tumors
• A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
• DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
• A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
• Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia
• Inqovi Maintenance Therapy in Myeloid Neoplasms
• GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
• 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors
• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
• Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
• Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
• A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
• Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
• A Phase 1b Study of ZN-c3 in Chinese Subjects
• Combination Immunotherapy in Rare Cancers Under InvesTigation
• A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
• HLX208 (BRAF V600E Inhibitor) in Combination With Trimetinib in Patients With Advanced Solid Tumors
• Treatment of Advanced and Metastatic Solid Tumors With MIL97
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
• Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
• A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
• Clinical Study of JS201 in Patients With Advanced Malignant Tumors
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
• Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
• A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
• A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
• The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
• A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
• A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
• GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
• A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
• CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
• A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
• A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
• A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
• Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
• A Study of NB003 in Patients With Advanced Malignancies
• Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
• SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
• Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
• ECP-1014 Treatment for Patients With Solid Tumor Cancers
• A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
• A Study of CBP-1018 in Patients With Advanced Solid Tumors
• XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
• A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
• Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
• Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors
• ALPN-202 With PD-1 Inhibition in Advanced Malignancies
• Study of IBI323 in Patients With Advanced Malignancies
• CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
• HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
• A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
• A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
• IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
• Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
• A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
• A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
• Depth of Necrosis in Normal Cervical Epithelium After 85% Trichloroacetic Acid (TCA) Application
• A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
• A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
• Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors
• Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
• Study Of ATRN-119 In Patients With Advanced Solid Tumors
• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
• Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
• B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
• Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
• XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors
• Radiosurgery Before Surgery for the Treatment of Brain Metastases
• Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
• Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
• Study of ESG401 in Adults With Solid Tumors
• Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
• A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.
• FHD-286 in Subjects With Advanced Hematologic Malignancies
• A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
• ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
• Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
• A Phase I Study of AL8326 in Advanced Solid Tumor
• A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
• A Study of DT2216 in Relapsed/Refractory Malignancies
• Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
• Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
• First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
• A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
• Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
• Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies
• A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
• The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor
• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
• Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
• Study of AK112 in the Treatment of Advanced Gynecological Tumors
• Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
• A Study of MRG003 in Patients With Advanced Solid Tumors
• Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
• A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors
• Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
• A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
• Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
• A Phase I, Single Center, Open-label Clinical Pharmacology Study to Evaluate the Effect of Tipifarnib on Cardiac Safety in Subjects With Advanced Solid Malignancies
• Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
• TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
• A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
• A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
• Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
• A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
• Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
• A Study of Q-1802 in Patients With Advanced Solid Tumors
• A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Solid Tumors.
• Study of RP-6306 in Advanced Solid Tumors
• Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
• Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
• A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
• A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
• A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
• Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
• Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
• Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
• Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
• HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Advanced Cancer Patients; A Multi-Centre, Randomised-Controlled Trial
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
• Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
• Study of Magrolimab in Participants With Solid Tumors
• Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
• A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
• A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours
• Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
• Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
• Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors
• Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
• Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
• A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
• Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases
• A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
• Endoscopic Ultrasound Guided Coeliac Plexus Neurolysis for Cancer Pain
• PF-07284892 in Participants With Advanced Solid Tumors
• Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
• Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
• A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
• Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
• Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
• A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
• Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
• Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
• Study of Magrolimab Combinations in Participants With Myeloid Malignancies
• Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
• Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
• A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
• Effect of Dexmedetomidine on Perioperative Internal Environment and Rehabilitation of Patients Undergoing Gastrointestinal Malignant Tumor Resection
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
• Intra-tumor Injection of Drug-eluting Microspheres
• The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
• Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
• Mirtazapine in Cancer-related Poly-symptomatology
• This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors
• Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
• First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
• A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.
• Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
• 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
• Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia
• SGM-101 in Colorectal Brain Metastases.
• A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
• BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker
• Intraoperative Tumor Margin Identification With ICG Dye Imaging
• Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
• Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
• A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours
• Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
• A Study of CBP-1008 in Patients With Advanced Solid Tumor
• An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
• Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
• A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
• Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
• Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies
• Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
• Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
• Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47 Antibody
• Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
• 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
• Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
• JAB-3312 Activity in Adult Patients With Advanced Solid Tumors
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
• Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
• Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
• Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
• Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
• Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors
• Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
• A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
• Combining Epigenetic And Immune Therapy to Beat Cancer.
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
• A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
• CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
• CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
• A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
• FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
• Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors
• A Study of PY314 in Subjects With Advanced Solid Tumors
• CAR-T for r/r Malignant Tumors in Children
• This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
• Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
• Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）
• A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
• Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
• Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
• A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
• A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
• SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
• Study of HL-085 in Patients With Advanced Solid Tumor Tumors
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
• A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
• A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
• First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
• A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
• Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor
• Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
• A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
• Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
• A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
• A Clinical Study of MIL93 in Solid Tumors.
• An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
• A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
• A Study of SGN-STNV in Advanced Solid Tumors
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
• Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
• ARX517 in Subjects With Advanced Solid Tumor
• NL-201 in Patients With Relapsed or Refractory Cancer
• A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
• LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
• Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
• A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
• Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
• A Clinical Study of MIL95 in Advanced Malignancies.
• BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
• Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• NeoTIL in Advanced Solid Tumors
• Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
• A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
• Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Biliary Tract Carcinomas
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
• A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
• ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
• Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
• ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
• A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
• Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
• AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
• Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
• Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
• REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
• Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors
• First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors
• Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy
• A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
• Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene
• 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
• A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
• The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
• Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors
• Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
• BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
• A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
• Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
• A Phase I Study of JS108 in Patients With Advanced Solid Tumors
• A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
• Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
• A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
• A Study of GFH009 in Patients With Hematologic Malignancies
• Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
• Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radio
• A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
• A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation
• Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
• Study to Evaluate D-1553 in Subjects With Solid Tumors
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
• Open-Label Surufatinib in European Patients With NET
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
• First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors
• Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
• Lidocaine And Neuromonitoring in Thyroid Surgery
• Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
• First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
• Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies
• Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
• Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors
• Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
• FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
• CRAFT: The NCT-PMO-1602 Phase II Trial
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
• A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
• Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
• A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
• Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
• Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
• CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
• RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
• Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
• Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies
• Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
• A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer
• A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
• A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
• A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
• CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
• Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy
• First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
• Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
• A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
• ADG116 in Patients With Advanced/Metastatic Solid Tumors
• Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
• Study of RP-3500 in Advanced Solid Tumors
• PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
• A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
• Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
• Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
• Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
• Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
• 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
• A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
• Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
• Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
• PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
• Propofol vs Sevo for Paediatric Tumor Surgery
• Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
• A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
• A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
• Safety and Early Signs of Efficacy of IL12-L19L19.
• Ketamine or Placebo in Patients With Major Depression and Advanced Cancer
• Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
• Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
• Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
• HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
• Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
• Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
• High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
• A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
• First in Human Study of M6223
• Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
• Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
• Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors
• Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
• Testing the Safety of CB-5339 in Patients With Cancer
• A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
• A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
• Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
• A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
• 5-aminolevulinic Acid In Advanced Malignancies
• A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
• Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
• Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
• A Study of TY-302 in Patients With Advanced Solid Tumors
• PTX-35 in Patients With Advanced Solid Tumors
• A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer
• A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
• A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
• PLATFORM Study of Precision Medicine for Rare Tumors
• A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
• A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
• JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
• Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
• A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours
• A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
• Cabozantinib in High Grade Neuroendocrine Neoplasms
• A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
• A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
• Afatinib in Advanced NRG1-Rearranged Malignancies
• Study of ASN004 in Patients With Advanced Solid Tumors
• Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
• First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
• Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
• Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment
• Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
• FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
• Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
• A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
• Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
• A Study of SGN-B6A in Advanced Solid Tumors
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
• A Study of KC1036 in Patients With Advanced Solid Tumors
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
• OH2 Injection in Solid Tumors
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
• Phase I Study in Advanced Malignancies With 5-ALA
• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
• A Study of MSB0254 Injection in Advanced Solid Tumors
• Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
• Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
• Study of SRF388 in Patients With Advanced Solid Tumors
• Testing the Safety of CB-5339 in Patients With Cancer
• Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
• Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor
• Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
• A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
• Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
• A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
• Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
• Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
• Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
• A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
• A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
• A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
• Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
• A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
• Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 in Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors
• A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
• ATG-008 Combined With Toripalimab in Advanced Solid Tumors
• Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
• Study of SRF617 in Patients With Advanced Solid Tumors
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
• A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
• First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
• Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL 2
• The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
• MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery
• QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
• A Study of CSPCHA131 in Patients With Advanced Solid Tumor
• A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
• Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
• A Phase I/II Study of TJ004309 for Advanced Solid Tumor
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
• ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
• Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
• Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection
• The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors
• Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
• Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies
• Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)
• A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
• Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
• Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
• Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
• Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies
• Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
• Study of AMG 650 in Adult Participants With Advanced Solid Tumors
• Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
• A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
• Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
• Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
• Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
• A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
• Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
• Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
• Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
• Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
• Chemoradiotherapy in Unresectable Esophageal Cancer
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
• Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
• Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
• Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
• A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
• A Study of MSB2311 in Advanced Solid Tumors
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
• Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
• Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
• MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors
• Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
• CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
• Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
• 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
• Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
• Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
• A Trial of ZL-1201 in Subjects With Advanced Cancer
• A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Positive Solid Tumors
• RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
• Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
• An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
• A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
• Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.
• A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
• GM-CSF With Post-Transplant Cyclophosphamide
• Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
• Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
• Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
• A Study of CS3005 in Advanced Solid Tumors
• Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
• A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
• Trial of NanoPac Focal Therapy for Prostate Cancer
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
• A Monotherapy in Subjects With Advanced Solid Tumors
• A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)
• Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
• Pantoprazole in Cisplatin Nephrotoxicity
• Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
• A Study of Anlotinib in Subjects With Advanced Malignancy
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
• APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
• Study of NK Combined With Chemotherapy for Advanced Solid Tumor
• Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
• A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
• Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Rhabdomyosarcoma in Pediatric Patients, T.O.A.S.T. I.T. Study
• Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
• A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
• A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
• A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
• Study of the Impact of DPD Activity on the Efficacy of Capecitabine
• A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
• WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
• Cabozantinib and Nivolumab for Carcinoid Tumors
• BP1001-A in Patients With Advanced or Recurrent Solid Tumors
• Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
• CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
• A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
• Safety of ABM-1310 in Patients With Advanced Solid Tumors
• Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
• Futibatinib in Patients With Specific FGFR Aberrations
• Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
• An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
• Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
• MAX-40279-01 in Patients With Advanced Solid Tumors
• Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
• Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
• The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
• A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
• Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
• A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
• Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
• A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
• Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
• M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
• Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
• A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
• Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
• Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies
• A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
• A Study of CS3002 in Subjects With Advanced Solid Tumors
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
• A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
• A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors.
• A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors
• A Study in Subjects With Advanced Solid Tumors
• Cryoablation for the Treatment of Metastatic Cancer
• A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
• Study of DS-7300a in Participants With Advanced Solid Malignant Tumors
• Evaluation of AP-002 in Patients With Solid Tumors
• Study of DF1001 in Patients With Advanced Solid Tumors
• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
• Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
• Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer
• A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
• Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer
• Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
• HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
• Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
• Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression
• MAX-10181 Given Orally to Patients With Advanced Solid Tumor
• Anti-CD137 Monoclonal Antibody in Patients With Advanced Cancer
• Cordotomy in Reducing Pain in Patients With Advanced Cancer
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
• MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
• A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
• Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
• Precision Medicine for Patients With Identified Actionable Mutations
• Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
• A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
• A Study of CPI-0209 in Patients With Advanced Tumors
• Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer
• C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
• Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
• Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
• The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
• Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer
• Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Di
• Sirolimus for Cowden Syndrome With Colon Polyposis
• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
• Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
• A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
• Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
• Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
• Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
• Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
• Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
• Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
• Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
• Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
• Indocyanine Green (ICG) Guided Tumor Resection
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
• GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
• Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
• A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
• FPT155 in Patients With Advanced Solid Tumors
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm
• Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
• A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
• Study to Evaluate CCS1477 in Haematological Malignancies
• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
• First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia
• Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
• A Phase 1 Study of HS-10342 In Patients With Advanced Solid Tumor
• Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
• Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
• A Phase I Trial of Simmitinib in Advanced Solid Tumors
• Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies
• Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males
• RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study
• To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors
• Dual Vaccine Trial in Myeloproliferative Neoplasms
• A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
• Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors
• Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors
• Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
• A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
• A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors
• A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor
• Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
• Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
• Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
• High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
• A Study of SHR-1501 in Patients With Advanced Tumors
• Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours
• Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
• 68-Ga-FAPI PET Imaging in Malignancy
• PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
• BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
• Safety and Efficacy Study of IMSA101 in Refractory Malignancies
• Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
• A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
• Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
• Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
• A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors
• A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
• A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
• Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
• Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
• A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
• Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
• A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
• Genetic Testing in Guiding Treatment for Patients With Brain Metastases
• Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET
• Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
• A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
• PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
• Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
• Safety Study of SLC-391 in Subjects With Solid Tumors
• A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
• Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC
• Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
• Phase I Study of Hemay102 in Patients With Advanced Solid Tumors
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
• A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
• Phase I Study of HL-085 in Patients With Advanced Solid Tumors
• Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
• Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia
• Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
• Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
• Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
• A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
• Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Soft Tissue or Bone Sarcoma Metastatic to the Lungs
• Study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumors
• Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
• Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
• Study of GS-1423 in Participants With Advanced Solid Tumors
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
• Study of FCN-437c in Patients With Advanced Solid Tumors
• Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
• HPV-SAVE: 9-Valent HPV Vaccine for High-Grade Anal Dysplasia
• Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
• Trial of DFP-14927 in Advanced Solid Tumors
• A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
• Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
• A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
• Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
• Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer
• A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
• Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
• A Study of OKI-179 in Patients With Solid Tumors
• 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
• Anlotinib in Advanced Solid Tumors With FGFR Alteration
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
• Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
• Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
• Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
• A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
• Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
• A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
• Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
• A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)
• HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
• Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors
• Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
• Fruquintinib in Combination With Sintilimab in Patients With Advanced Solid Tumor
• Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
• Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
• Phase 1 Study of PTX-100 in Patients With Advanced Malignancies
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
• Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
• Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
• Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
• A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
• A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
• Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
• Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
• The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
• Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
• VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
• The Clinical Significance of Ovarian Function Detection and Protection in Fertility Preservation Surgery for Ovarian Malignancy
• Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
• Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
• Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
• Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
• Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
• Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
• First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
• Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
• Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
• Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
• A Study of SHR-A1403 in Patients With Advanced Solid Tumor
• Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
• IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
• A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
• AMG 404 in Patients With Advanced Solid Tumors.
• Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
• Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
• Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
• A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
• Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
• Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
• Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
• INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
• Durvalumab and Tremelimumab for Pediatric Malignancies
• Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
• Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
• Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
• A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
• A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
• Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
• SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
• Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
• Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors
• Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
• Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
• Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
• A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors
• A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
• Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
• Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
• A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
• Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
• Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
• Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
• Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer
• Evolution of Thromboelastography During Tranexamic Acid Treatment
• Early Palliative Care for Patients With Haematological Malignancies
• A Study of ASP1951 in Subjects With Advanced Solid Tumors
• Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
• A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
• Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
• Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
• Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
• Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
• A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
• A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
• SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
• A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
• Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
• SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
• CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
• A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
• First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
• TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
• Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors
• A Study of LY3415244 in Participants With Advanced Solid Tumors
• Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors
• Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies
• Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
• Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors
• A Study of CS1001 in Subjects With Advanced Solid Tumors
• Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
• A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
• A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm
• Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
• Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
• GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
• Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
• CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients
• Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
• the Efficacy and Safety of Sugammadex in Children 0-2 Years Old
• Hepatic Impairment Study for Lorlatinib in Cancer Patients
• A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
• ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
• Study of Avelumab-M3814 Combinations
• Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
• Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
• A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies
• Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
• Study of TP-3654 in Patients With Advanced Solid Tumors
• Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
• Compassionate Use Study of Tenalisib (RP6530)
• SHR-1701 in Metastatic or Locally Advanced Solid Tumors
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
• PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
• Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
• Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
• Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
• Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
• Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.
• Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
• Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
• Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
• Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
• REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
• Phase II Trial of AZD6738 Alone and in Combination With Olaparib
• 9-ING-41 in Patients With Advanced Cancers
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
• COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.
• Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
• A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
• Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
• A Study of TAK-981 in Participants With Relapsed/Refractory Solid Tumors or Non-Hodgkin Lymphoma (NHL)
• QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
• A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
• Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
• The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
• Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
• A Study of Injection HB002.1T in Subjects With Solid Tumor
• Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
• Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
• Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
• M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
• First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
• A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
• Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
• REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
• Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
• SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
• A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
• Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
• Combination Chemotherapy in Patients With Newly Diagnosed BPDCN
• Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
• A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies
• Study of BAY1834942 in Patients With Solid Tumors
• A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
• A Study of HQP1351 in Patients With GIST or Other Solid Tumors
• Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
• A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
• A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
• Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
• NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
• A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
• Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
• Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
• Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Participants With Advanced, Metastatic, or Recurrent Cancer
• Study of EOC317 in Chinese Patients With Advanced Solid Tumors
• To Study the Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare Improvement in Late-stage Solid Cancer Subjects
• Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
• Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
• The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
• Dual-Time Point (DTP) FDG PET CT for the Post-Treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy
• This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
• A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
• Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
• IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
• Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
• Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
• Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
• IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
• A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
• The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
• A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
• A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
• Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
• SGT-53 in Children With Recurrent or Progressive CNS Malignancies
• A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
• Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
• A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML
• A Study of IBI310 in Treatment of Patients With Advanced Solid Tumors.
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
• Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
• Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis
• A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
• FID-007 in Treating Participants With Advanced Solid Tumors
• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
• A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
• Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
• A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
• Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
• Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
• ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
• Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
• Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
• A Study of CS1002 in Subjects With Advanced Solid Tumors
• A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
• Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
• Study of ASTX029 in Subjects With Advanced Solid Tumors
• Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
• Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
• A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
• IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
• A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
• Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
• Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
• Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
• TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
• A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
• A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
• Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology
• A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
• Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
• Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma
• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms
• Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
• K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor
• 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
• Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
• Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
• Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
• A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
• MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
• Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
• Study to Evaluate the Safety and Anti-tumor Activity of SCC244
• Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
• A Phase I Study of MSB2311 in Advanced Solid Tumors
• Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
• Pre-Operative Single Shot Rectus Sheath Block
• Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
• Investigation of 68GaPSMA PET/CT as an Imaging Biomarker in Solid Tumors
• AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
• Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer
• Postpartum HPV Vaccination
• Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
• A Study of PTS for Patients With Solid Tumors
• Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
• Palbociclib and Cetuximab in Metastatic Colorectal Cancer
• Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
• Study of Nivolumab for Advanced Cancers in India
• A Study of E7130 in Participants With Solid Tumors
• Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
• Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
• Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
• Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers
• Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
• First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
• A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
• Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
• M7824 in Subjects With HPV Associated Malignancies
• Imaging of Advanced Tumours Using [131]I-IAZA
• Role of Axumin PET Scan in Germ Cell Tumor
• Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
• A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
• Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
• AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Patients With ALK-Positive or ROS1-Positive Solid Tumors
• Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
• HPV Anti-CD40 RNA Vaccine
• A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
• Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
• A Study of ASN007 in Patients With Advanced Solid Tumors
• Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
• Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
• Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
• Avelumab in Refractory Testicular Germ Cell Cancer.
• The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
• Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
• Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
• Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
• 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
• Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
• 68Ga PSMA in Preprostatectomy Patients
• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
• TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
• A Study of MORAb-202 in Participants With Solid Tumors
• APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
• Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
• The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
• Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
• IMX-110 in Patients With Advanced Solid Tumors
• Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
• Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
• Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
• Dexamethasone in Controlling Dyspnea in Patients With Cancer
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
• 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
• Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
• Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
• Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
• A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
• Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
• A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
• Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
• Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
• A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
• An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
• Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
• Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
• A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
• A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
• Safety and Efficacy Evaluation of IM19 Cells
• A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
• Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
• A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
• A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
• Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
• A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
• Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
• Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
• A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
• A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors
• A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
• Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
• A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
• AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
• Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
• A Study of PLX2853 in Advanced Malignancies.
• A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
• IACS-010759 in Advanced Cancers
• Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
• Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
• PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
• HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
• Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
• NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
• Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
• INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
• Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma
• Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
• A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
• Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
• Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
• Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
• Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
• Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
• IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
• A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
• Study of E7386 in Participants With Selected Advanced Neoplasms
• A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
• Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
• Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
• A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
• Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
• Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
• A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
• AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
• A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
• A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
• Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
• Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer
• A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
• Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
• Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
• Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event
• A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors
• Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
• A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
• A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
• A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
• Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
• Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
• M3541 in Combination With Radiotherapy in Subjects With Solid Tumors
• Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
• Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
• Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
• Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL)
• Neuromuscular Blockade on Shoulder Pain of Elderly
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
• A Trial of HTI-1090 in Subjects With Advanced Solid Tumors
• Study of E7389 Liposomal Formulation in Participants With Solid Tumor
• Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
• Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
• COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
• Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
• Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for Metastatic Pain in Thoracic Vertebral Body
• Oral Supplementation to Enhance Recovery Pilot Study
• Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
• Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
• Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
• A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
• Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit
• Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
• Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
• Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
• Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
• A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
• Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
• Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
• Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft
• Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
• Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
• TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
• The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
• Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
• Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
• Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining
• Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
• Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
• Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
• Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
• Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
• Test-Retest of (18)F-Fluoroazomycin Arabinoside ([18F]FAZA) PET-CT of Solid Tumors
• A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
• NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
• First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
• Selumetinib and Olaparib in Solid Tumors
• A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies
• Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
• A Study of HMPL-453 in Patients With Advanced Solid Malignancies
• Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
• To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
• Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
• Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
• Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
• Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
• Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
• QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
• Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
• A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
• Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
• Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
• FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
• Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
• Investigation of Sugammadex in Outpatient Urological Procedures
• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
• OMO-1 in Solid Malignancies
• Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
• Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
• Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
• Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
• Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children
• Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
• Imaging With a New Agent That Finds a Cancer Protein Called HER2
• Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
• ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
• Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging
• Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
• Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
• Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
• A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics
• This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With
• A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
• Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
• Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
• Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
• A Study of AK-01 (LY3295668) in Solid Tumors
• Savolitinib vs. Sunitinib in MET-driven PRCC.
• Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
• A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
• Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
• A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
• Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
• Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
• A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
• P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
• A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
• A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Study of Talazoparib in Patients With Advanced Solid Tumors
• Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
• Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
• Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
• PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
• Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
• A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
• Improving Function,Welfare of Late-stage Cancer Subjects by ACC
• Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
• Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
• First-in-Human Study of KO-947 in Non-Hematological Malignancies
• Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
• A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
• Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• ODM-207 in Patients With Advance Solid Tumours
• Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
• Neoadjuvant Listeria or Daratumumab in Prostate Cancer
• A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
• Phase 2 Study of ONC201 in Neuroendocrine Tumors
• General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial
• A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
• Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
• Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
• Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
• Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
• A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
• Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
• Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
• Epidural Anesthesia-analgesia and Long-term Outcome
• Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
• Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
• Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
• A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
• Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
• Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
• Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
• Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
• Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
• MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
• The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
• To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
• 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
• A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
• Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy
• A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics
• Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
• Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
• RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
• Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
• HDCRT Plus Pembrolizumab in Advanced Malignancies
• Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
• Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
• Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
• Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
• A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
• A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
• Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
• Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
• A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
• Phase I Study of SHR7390 in Patients With Advanced Solid Tumors
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
• A Study of TAS-116 in Patients With Solid Tumors
• A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
• Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
• Study of ASN003 in Subjects With Advanced Solid Tumors
• Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
• Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
• A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
• A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroe
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
• Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
• Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients
• A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
• Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
• Effectiveness of Nefopam in Breast Cancer Surgery
• PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
• Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
• Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
• Study of Ixazomib and Erlotinib in Solid Tumors
• Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
• Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
• A Study of SC10914 in Patients With Advanced Solid Tumors
• A Study of LY3200882 in Participants With Solid Tumors
• First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
• Ribociclib (LEE011) Rollover Study for Continued Access
• Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
• Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
• The Drug Rediscovery Protocol (DRUP Trial)
• A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
• Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy
• Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
• A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
• Imiquimod Treatment of High-grade CIN
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
• Kanitinib in Treating Patients With Advanced Solid Tumors
• Lenvatinib and Capecitabine in Patients With Advanced Malignancies
• Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
• Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
• Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
• Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
• A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
• Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
• Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
• Palbociclib In Progressive Brain Metastases
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
• A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers
• Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma
• Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
• A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
• Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
• Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
• A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
• A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
• A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
• Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
• KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
• Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
• Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
• Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
• Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
• A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
• E7 TCR T Cells for Human Papillomavirus-Associated Cancers
• A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
• Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
• Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
• POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
• Study of CD133KDEL Toxin in the Treatment for Solid Tumors
• Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
• Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
• A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
• Ceramide NanoLiposome in Patients With Advanced Solid Tumors
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
• A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
• A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participa
• Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
• Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma
• A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
• Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
• Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy
• Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
• Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
• Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
• PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
• Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery
• RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
• Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
• A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
• Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
• A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
• CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
• Durvalumab in Pediatric and Adolescent Patients
• A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
• Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficienc
• Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
• A Study of AL2846 on Tolerance and Pharmacokinetics
• A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
• Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
• Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
• Intraoperative Imaging of Pituitary Adenomas by OTL
• Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
• Vevorisertib (ARQ 751) (4440-001) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations
• A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
• A Phase I Trial of HS-10241 in Solid Tumors
• Perioperative Systemic Therapy in Patients Undergoing Surgery With HIPEC for Colon Cancer With Peritoneal Metastases: the CAIRO6 Study.
• Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
• Personalized PRRT of Neuroendocrine Tumors
• Nano MRI on 7 Tesla in Rectal and Breast Cancer
• Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
• A Study of ERY974 in Patient With Advanced Solid Tumors
• Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
• Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
• Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
• A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
• A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
• DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
• A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
• Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
• Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
• Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
• Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
• Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
• A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
• Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
• Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
• Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
• A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS)
• The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
• A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
• Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
• Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
• A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
• Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
• A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
• Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
• An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
• A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
• Genetic Predictors of Benefit to Pembrolizumab
• Consolidation Therapy in Patients With Hematologic Malignancies
• A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
• Consolidation Therapy in Patients With Metastatic Solid Malignancies
• PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
• Cyclosporine Plus Methotrexate or Alemtuzumab
• MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors
• Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
• CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
• Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
• Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
• Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
• Study of DS-1123a in Advanced Solid Tumours
• Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
• Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
• Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
• A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
• Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
• A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
• A Study of SHR6390 in Advanced Solid Tumor Patients
• Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
• To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
• Phase I Study of PDR001 in Patients With Advanced Malignancies.
• CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)
• Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
• A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
• A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
• Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
• Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
• A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
• Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
• Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol
• Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
• Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
• A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
• Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
• Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
• A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
• Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
• Impact of Anesthesia Maintenance Methods on Long-term Survival
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
• T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
• PF-06671008 Dose Escalation Study in Advanced Solid Tumors
• An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
• BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
• A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
• A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
• Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
• Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
• Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
• Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
• Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
• Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
• Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury
• Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
• Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
• Eribulin and Lenvatinib in Advanced Solid Tumors
• A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
• Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
• Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
• A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
• Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
• A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
• 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
• Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract
• Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
• Intraoperative Imaging of Pituitary Adenomas by OTL
• The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
• A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
• Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
• A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
• Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
• Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
• LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
• Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
• Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
• Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
• Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms
• Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
• Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma
• A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
• A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
• Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer
• A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
• Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
• A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
• Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
• A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
• Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
• Study of INCB053914 in Subjects With Advanced Malignancies
• Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
• Tumor Hypoxia With HX4 PET in Several Diseases
• Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer
• Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients
• Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
• QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
• A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
• Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• A Study of SAR428926 in Patients With Advanced Solid Tumors
• A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
• Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy
• Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
• (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
• Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
• A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
• Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)
• Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
• ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
• Use of Lidocaine in Endoscopic Submucosal Dissection
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
• Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
• Study of E7046 in Subjects With Selected Advanced Malignancies
• Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
• HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
• A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
• Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
• Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
• Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
• Extended Use of Sodium Bicarbonate in Patients With Cancer
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
• A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
• Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
• Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
• A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
• Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
• A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
• Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
• A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
• Sublingual Fentanyl for the Management of Breakthrough Pain
• Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
• A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
• (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
• Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
• A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
• Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
• Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
• Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
• Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
• Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
• Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
• A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
• Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
• Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy
• A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
• A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.
• Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
• A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291
• Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
• A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
• An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
• Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
• Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Ca
• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
• Study of the CD40 Agonistic Monoclonal Antibody APX005M
• Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
• A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
• Study of Regorafenib and Sildenafil for Advanced Solid Tumors
• Ceritinib Rare Indications Study in ALK+ Tumors
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
• A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
• A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
• Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
• Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
• Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
• Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
• Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
• Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
• Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
• A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
• CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
• Theranostics: 68GaDOTATOC and 90YDOTATOC
• Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
• Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
• Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
• Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
• Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
• Safety Study of AMG 228 to Treat Solid Tumors
• A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
• A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
• A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
• Survivorship Promotion In Reducing IGF-1 Trial
• An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
• The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
• A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
• Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
• Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
• A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
• Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
• Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
• A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
• MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
• Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
• Discovery Stage IND EXEMPT Clinical Study About ABIRATERONE ACETATE and Single Nucleotide Polymorphisms
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
• Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
• Regorafenib Phase I Study in Mainland Chinese Patients
• Prospective, Observational, Real-world Oral Malignant Tumors Study
• Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
• Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
• Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
• Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
• Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
• Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
• Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
• Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
• Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin
• A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
• The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
• Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
• Safety Study of SEA-CD40 in Cancer Patients
• Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients
• Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
• Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
• Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
• Phase 1a/1b BGB-290 for Advanced Solid Tumors.
• Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
• 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
• Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
• Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
• Phase I Study of Intravenous Artesunate for Solid Tumors
• Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
• A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
• Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment
• A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
• Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
• Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
• Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
• Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
• Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
• Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
• Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
• Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
• Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies
• Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
• Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
• Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
• Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
• Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
• A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
• Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
• Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
• Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
• Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
• Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
• Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
• Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
• Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
• Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
• A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
• RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
• Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
• Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
• A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
• NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
• A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
• Safety Study of Vx006 Vaccine in Solid Tumor Patients
• Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
• Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
• Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
• Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
• De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
• Indocyanine Green for Solid Tumors
• First in Human Study of M4344 in Participants With Advanced Solid Tumors
• Phase 1 Study of E7090 in Subjects With Solid Tumor
• Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
• Tagraxofusp (SL-401) in Patients With CMML or MF
• A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
• A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors
• A Study of LY3022855 In Participants With Breast or Prostate Cancer
• An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
• Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
• Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours
• Icotinib for Completed Resected IB NSCLC With EGFR Mutation
• A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
• A Phase I Study of TAS-102 in Solid Tumors
• ONO-4538 Phase I Study in Patients With Solid Tumor
• ONO-4538 Phase I Study in Patients With Solid Tumor
• Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
• Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I
• Oral ONC201 in Treating Patients With Advanced Solid Tumors
• Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
• A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
• Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
• Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
• Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
• A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
• A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
• Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
• Malignancies in Transplanted Patients
• Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
• Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
• Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
• The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
• Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System
• A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
• HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
• Adjuvant HIPEC in High Risk Colon Cancer
• Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
• Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
• A Study of DCC-2701 in Participants With Advanced Solid Tumors
• Olaparib and Radiotherapy in Inoperable Breast Cancer
• Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
• Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
• Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
• Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours
• A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
• A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
• A Study of LY3164530 in Participants With Cancer
• Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
• Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
• Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
• Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer
• Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
• A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
• Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
• Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
• Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
• Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
• Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
• TAP Versus Thoracic Epidural in Major Abdominal Resections
• Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
• Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)
• Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
• IDH1 Peptide Vaccine for Recurrent Grade II Glioma
• Open Label Study of DS-5573a
• Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
• Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
• Evaluation of SAR408701 in Patients With Advanced Solid Tumors
• Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
• Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
• Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
• Phase I Study of Oral DFP-11207 in Solid Tumors
• Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
• ODSH + ICE Chemotherapy in Pediatric Solid Tumors
• Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
• First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations
• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
• A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
• Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
• M6620 First in Human Study
• Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
• (IMPACT II) Molecular Profiling and Targeted Therapy in Treating Patients With Metastatic Cancer
• αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
• A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
• A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
• Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
• N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
• Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
• Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
• Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
• Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
• Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
• A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
• Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
• Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
• A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
• Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
• Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
• A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
• A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
• Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
• Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• A Study Of PF-06664178 In Patients With Advanced Solid Tumors
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
• Treg Cells for AGVHD in Non-myeloablative UCB Transplant
• A Study of LY2835219 in Participants With Cancer
• An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Ful
• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
• Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
• SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
• RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
• A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
• Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
• Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
• Intranasal Dexmedetomidine Premedication
• Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
• Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy
• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
• Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
• ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
• Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
• A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
• Regorafenib and Cetuximab in Patients With Advanced Malignancy
• NAC to Prevent Cisplatin-induced Hearing Loss
• A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
• A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
• ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
• 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
• Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
• HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)
• Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor
• A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
• Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
• A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
• A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
• Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
• PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
• PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
• Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
• Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
• Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
• PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
• A Study of TAS-120 in Patients With Advanced Solid Tumors
• A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
• A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
• Safety of Romiplostim (Nplate®) Following UCBT
• Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors
• Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
• A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
• Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies
• MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
• Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
• Safety and Effectiveness of Regorafenib
• Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
• A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
• 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
• An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
• Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
• Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
• Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
• High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia
• Maintenance Treatment With Capecitabine in Colorectal Cancer Patients
• Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
• A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
• A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
• Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
• A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
• Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
• Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
• Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
• LDE225 for Patients With PTCH1 or SMO Mutated Tumors
• A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
• A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
• A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
• Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy
• Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
• A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
• Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
• Relative Bioavailability of Pimasertib in Cancer Patients
• Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
• A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies
• A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
• SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy
• 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
• Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
• Phase 1 Trial of CXD101 in Patients With Advanced Cancer
• Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"
• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
• Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
• Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
• First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
• Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
• Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
• Phase I Study of Safety and Immunogenicity of ADU-623
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
• A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
• Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
• Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
• A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
• Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
• Japanese Phase 1 Trial of Sym004 in Solid Tumors
• A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
• Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
• Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
• To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
• Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
• Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
• Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
• A Study of ABT-165 in Subjects With Solid Tumors
• A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients
• An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
• XL999 Administered Intravenously to a Subject With Advanced Malignancies
• A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
• Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
• Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
• A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
• An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
• A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
• Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
• Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
• Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
• Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
• Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia
• To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
• Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.
• To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
• Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
• A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
• Phase 1 Study of OTS167 in Patients With Solid Tumors
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
• Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors
• Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
• A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
• Chemoimmunotherapy and Radiation in Pancreatic Cancer
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
• To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
• A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
• Heart Safety Study of Ondansetron in Children Receiving Chemotherapy
• Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
• Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
• Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
• Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
• A Study Of PF-06263507 In Patients With Advanced Solid Tumors
• Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
• Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer
• Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)
• Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
• A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
• Dose Escalating Study for Amphinex-based PCI of Bleomycin.
• Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
• Phase II Trial for Large ER-Negative Breast Cancers
• Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
• Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
• Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
• Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
• Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
• Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia
• Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
• Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
• Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors
• A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
• D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
• A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
• Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
• A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
• An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
• Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
• Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
• Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
• Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies
• BKM120 for Patients With PI3K-activated Tumors
• A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
• Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
• 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
• A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
• Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia
• Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
• Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
• Cologne Cohort of Neutropenic Patients (CoCoNut)
• Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
• Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
• ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
• A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
• A Study of ARGX-110 in Participants With Advanced Malignancies
• Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
• Safety Study of MG1102 in Patients With Solid Tumors
• Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
• Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
• Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
• Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
• Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
• Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
• Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
• Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation
• Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
• Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
• Phase II Maraviroc for GVHD Prevention
• A Study of BBI503 in Adult Patients With Advanced Solid Tumors
• Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
• Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
• Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
• A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
• A Study of BBI608 in Adult Patients With Advanced Malignancies
• A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)
• An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
• A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
• 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
• A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
• Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
• A Phase I Study of Famitinib Malate in Patients With Solid Tumor
• Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
• A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
• A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
• Ipilimumab and Lenalidomide in Advanced Cancer
• Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
• Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
• AZD1775 for Advanced Solid Tumors
• ST1968 Intravenous (Weekly) in Solid Tumors
• An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
• Dasatinib and Crizotinib in Advanced Cancer
• Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
• Ipilimumab and Imatinib Mesylate in Advanced Cancer
• Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
• Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
• Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
• A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
• A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
• A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
• A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
• Study of LY2157299 in Japanese Participants With Cancer
• Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
• A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
• Phase I Platinum Based Chemotherapy Plus Indomethacin
• [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
• Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
• Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia
• Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
• A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
• Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
• A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
• A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
• Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
• A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
• A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
• Interleukin-2 in Metastatic Kidney Cancer
• Anti-EGFR Immunoliposomes in Solid Tumors
• Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
• A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
• Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
• PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
• A Study of LY3039478 in Participants With Advanced Cancer
• Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies
• Cabozantinib for Advanced Urothelial Cancer
• Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
• A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
• A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Adva
• Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
• Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
• A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
• PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
• GRN1005 for Brain Metastases From Breast or Lung Cancer
• An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
• SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma
• A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
• Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
• HPPH and PDT for Pleural Malignancy
• Colorectal Cancer Metastatic
• Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
• A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours
• Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
• A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
• Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
• 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
• Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
• A Study of LY3023414 in Participants With Advanced Cancer
• CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
• Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
• A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
• Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
• The Effect of Epidural Fentanyl on Immune Function
• Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
• MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
• Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
• Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
• Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
• Phase 1 Safety Testing of SAR405838
• Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
• Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
• Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
• Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
• Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
• A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
• Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
• A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
• Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
• Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
• Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
• Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and P
• A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
• Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
• A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
• Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies
• Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
• A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
• A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
• Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
• Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
• A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
• A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
• Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
• A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
• Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
• Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
• A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
• Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
• Cabozantinib in Advanced Solid Malignancies
• Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
• Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
• Drug Interaction Study of SAR302503 in Patients With Solid Tumor
• Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
• Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
• Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
• PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
• Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
• Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
• Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
• Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
• A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
• Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
• A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
• A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
• Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer
• Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
• A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)
• Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
• Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
• A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment
• Oxaliplatin for Children With Solid Tumors
• Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
• GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
• AMG 386 and Abiraterone for Advanced Prostate Cancer
• Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
• A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
• Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
• Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
• A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
• A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
• Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
• PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
• Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
• Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
• Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
• Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
• Erlotinib in Combination With Pralatrexate in Advanced Malignancies
• Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
• De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
• Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
• First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
• Metformin in Children With Relapsed or Refractory Solid Tumors
• Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment
• Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
• Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
• Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
• Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
• A Dose-Escalation Study in Participants With Advanced Cancer
• PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
• A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
• Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
• Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
• Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
• Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors
• A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
• Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
• Additive Homeopathy in Cancer Patients
• A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
• Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
• Clinical Trial of ARQ 761 in Advanced Solid Tumors
• Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
• Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
• Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
• A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
• A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
• Imaging Study for FdCyd and THU Cancer Treatment
• Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
• A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
• Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
• ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
• Study of ABT-700 in Subjects With Advanced Solid Tumors
• An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
• Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
• A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
• First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
• Pazopanib and ARQ 197 for Advanced Solid Tumors
• Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
• Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
• Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
• A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
• Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm
• Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
• Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
• Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
• A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
• A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
• MSC2015103B in Solid Tumors
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
• A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
• Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
• Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
• Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
• More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
• Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
• A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
• A Study of AMG 820 in Subjects With Advanced Solid Tumors
• MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
• The Effects of Lycopene on High Risk Prostatic Tissue
• Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
• ECI301 and Radiation for Advanced or Metastatic Cancer
• Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
• Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
• A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
• Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
• BN80927 in Patients With Advanced Malignant Solid Tumors
• Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
• Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
• A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)
• Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
• Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
• A Phase I Study of E7050 in Subjects With Solid Tumors
• The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
• A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
• Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
• Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
• Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
• Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
• NHS-IL12 for Solid Tumors
• A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
• Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
• An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
• Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
• A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
• Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
• Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
• An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
• Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
• Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
• Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors
• A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
• A Study of LY2584702 in Participants With Advanced Cancer
• A Study of LY2228820 in Participants With Advanced Cancer
• Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab
• The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
• Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors
• Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors
• Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
• Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies
• Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
• Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
• Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia
• Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
• PDM08 Clinical Trial in Advanced Solid Tumors
• Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
• Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
• A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
• Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
• Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
• Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
• Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
• A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
• A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
• Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
• Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
• MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
• Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
• Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
• BIBF 1120 and RAD001 in Solid Tumors - Phase I
• A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
• Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
• Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
• Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
• Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
• A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
• Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors
• Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
• Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
• Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
• Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
• Study of Tesetaxel in Japanese Patients With Solid Tumors
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
• Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
• Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer
• Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
• Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
• Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
• TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
• Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
• A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
• Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
• Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
• Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
• Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
• NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors
• A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
• A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
• Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
• A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
• BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
• GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
• Gemcitabine and CT-011 for Resected Pancreatic Cancer
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
• Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
• Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
• A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
• Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
• New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
• Sorafenib and TRC105 in Hepatocellular Cancer
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
• Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)
• Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
• A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
• Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
• AMG 319 Lymphoid Malignancy FIH
• A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
• Study of PM060184 in Patients With Advanced Solid Tumors
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies
• BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
• Safety Study of X-82 in Patients With Advanced Solid Tumors
• Study of EZN-2208 Pediatric Patients With Solid Tumors
• Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
• A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
• Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
• A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
• A Study of LY2875358 in Participants With Advanced Cancer
• AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
• A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
• Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
• A Study Of PF-04449913 Administered Alone In Select Solid Tumors
• A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
• Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
• A Safety Study in Participants With Advanced Solid Tumors
• Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
• Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
• Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia
• A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
• Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
• A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
• Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
• Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
• A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
• Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
• Safety of CHIR-258 (TKI258) in Advanced Solid Tumors
• Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
• The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
• Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
• Tapentadol in Chronic Malignant Tumour Related Pain
• A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
• Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
• Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
• Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
• Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
• A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
• A Study of AMG 337 in Subjects With Advanced Solid Tumors
• Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
• Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours
• Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
• A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
• Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
• Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies
• An Open-Label, Dose-Escalation Study of AZD2461
• AT13387 in Adults With Refractory Solid Tumors
• Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
• Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
• A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
• ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
• Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
• A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
• An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
• Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
• MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
• A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
• QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
• Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
• A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
• A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
• A Study in Advanced Cancer
• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
• Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets
• Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
• Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
• A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
• To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
• Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
• Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors
• Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
• Satraplatin and Vinorelbine in Advanced Solid Tumors
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
• A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the E
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
• Study of Everolimus (RAD001) in Combination With Lenalidomide
• Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
• Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
• Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
• A Phase 1 Study in Patients With Solid Tumors
• Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors
• Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
• Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
• A Dose-Escalation Study for Patients With Advanced Cancer
• A Study for Participants With Advanced Cancer
• Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
• Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
• Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
• Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
• Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
• A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
• Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
• Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
• Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
• Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
• A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
• A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
• To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors
• Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
• Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
• Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
• A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
• A Dose-escalation Study in Subjects With Advanced Malignancies
• Malignancy Meta Analysis for BRL49653
• Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
• Dose Escalation of IPI-493 in Hematologic Malignancies
• To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
• 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
• Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
• Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
• Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
• Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
• Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
• A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
• Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
• Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
• A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
• Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial
• Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells
• Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
• Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
• Trientine and Carboplatin in Advanced Malignancies
• Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
• Evaluation of Food Effect on Pharmacokinetics of Vismodegib
• High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
• Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
• Ixabepilone and Pemetrexed/Solid Tumors
• Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
• A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
• Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
• Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
• Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
• A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
• Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
• INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
• Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
• A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
• A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
• LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
• Notch Inhibitor in Advanced Cancer
• First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
• Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
• Lenalidomide and Paclitaxel in Advanced Solid Tumors
• A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• Bendamustine and Bevacizumab for Advanced Cancers
• Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
• Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
• Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
• Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
• Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
• A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
• Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
• GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
• A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
• Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
• Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
• Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
• Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
• Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
• 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
• A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
• Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
• An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
• Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
• Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
• Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
• Sorafenib Plus S-1 in Advanced Solid Tumors
• A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
• Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
• Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
• An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
• Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
• Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
• An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
• A Phase 1 Study in Participants With Advanced Cancer
• Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
• Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
• Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
• A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
• ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
• Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
• First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
• QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
• A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
• A Study of MEDI-575 in Patients With Advanced Solid Malignancies
• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
• Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
• A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
• Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
• Study in Advanced Solid Tumors
• Safety and Efficacy of LCL161 in Patients With Solid Tumors
• Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
• Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
• Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Lapatinib With Sirolimus or Metformin
• Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
• Effect of Cabazitaxel on the QTc Interval in Cancer Patients
• Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
• A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
• Everolimus and Capecitabine in Patients With Advanced Malignancy
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
• A Dose-escalation Study in Subjects With Advanced Malignancies
• A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
• A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
• AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
• A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
• A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
• Dose-range Finding Treosulfan-based Conditioning
• A Study in Advanced Solid Tumors
• Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
• Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
• A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
• HAI Abraxane With Gemcitabine and Bevacizumab
• Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
• Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
• Docetaxel and Sirolimus in Patients With Advanced Malignancies
• Anidulafungin in Patients With Hematologic Malignancies
• Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
• Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
• A Study of MORAb-003 in Patients With Solid Tumor
• Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
• A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
• Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue
• Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
• A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
• Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
• Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
• Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
• ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
• Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
• Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
• Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
• AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
• Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
• A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
• A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
• Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
• A First in Man Study of MABp1 in Patients With Advanced Cancers
• Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
• Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors
• Study of NMS-1116354 in Solid Tumors
• Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
• LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
• First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
• Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis
• Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
• A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
• Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
• Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
• Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
• Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
• Safety Study of PLX108-01 in Patients With Solid Tumors
• A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
• A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
• Study Evaluating SKI-606 in Subject With Solid Tumors
• Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
• A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
• 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
• Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
• Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
• Study of PKI-179 Administered Orally to Subjects With Solid Tumors
• Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
• A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
• Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
• Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
• Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
• A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
• Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
• A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
• Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
• High Dose Somatostatin Analogues in Neuroendocrine Tumors
• Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
• Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
• Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)
• A Study to Assess PV-10 Chemoablation of Cancer of the Liver
• AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
• Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
• The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
• Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
• A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
• Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
• Trial of MSC1936369B in Subjects With Solid Tumors
• Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
• A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
• HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
• Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies
• Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
• DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
• A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
• Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
• A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
• Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
• QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
• Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
• Study of KRN951 in Patients With Solid Tumors
• Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
• CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
• Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
• A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
• Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
• Study of MLN8237 in Participants With Advanced Solid Tumors
• Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
• Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
• A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
• Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
• Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
• Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
• Trial of Pimasertib in Hematological Malignancies
• STAT3 Inhibitor for Solid Tumors
• Maintenance Study on the Long Term Safety of XL999
• Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
• A Study Of PF-04449913 In Select Hematologic Malignancies
• A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
• CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
• Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
• Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
• Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
• A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
• Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors
• Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
• Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
• Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
• Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
• Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
• ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial
• Sirolimus and Cetuximab in Advanced Malignancies
• Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
• TTP607 in Refractory Solid Malignancies
• Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
• Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
• SORAVE - Sorafenib and Everolimus in Solid Tumors
• This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
• RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
• Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
• Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
• Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
• A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-
• A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
• Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
• Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
• Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
• Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
• A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
• A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
• Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
• Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
• A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
• A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
• Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm
• A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
• A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
• Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
• LY2275796 in Advanced Cancer
• rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
• Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
• Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
• Studying Fentanyl in Patients With Cancer
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
• Study of Erlotinib in Combination With Bortezomib
• Erlotinib in Combination With Cetuximab
• Study of Erlotinib in Combination With Dasatinib
• Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
• Pharmacologic Optimization of Voriconazole
• Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
• Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
• Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
• Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
• Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
• Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
• Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
• Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
• Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
• Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
• Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
• Study of AS1411 in Advanced Solid Tumours
• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
• A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
• Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
• Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
• Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
• Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
• Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
• Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
• A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)
• Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
• A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
• Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
• Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
• Study of DMXAA (Now Known as ASA404) in Solid Tumors
• A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
• Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
• Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
• A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
• Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
• Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
• Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
• A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
• CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
• A Study of of MORAb-004 in Subjects With Solid Tumors
• Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
• A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
• Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
• A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
• Methionine PET/CT Studies In Patients With Cancer
• Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
• Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
• Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
• A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
• A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
• A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
• Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
• Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
• Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
• Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
• Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
• Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
• A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
• Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
• AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
• A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
• Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
• Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
• Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
• Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
• Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
• Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
• Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
• Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
• Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
• A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
• Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
• A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
• S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
• Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
• A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
• A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
• RDEA119 and Sorafenib Combination Dose Escalation Study
• Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
• Infusional C-myb ASODN in Advanced Hematologic Malignancies
• Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
• A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
• Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
• A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies
• AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
• Study Evaluating Safety And Tolerability, Solid Tumor
• A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
• PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
• Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
• Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
• Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
• An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
• Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
• A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
• A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
• A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
• Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan
• A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
• Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
• A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
• A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
• Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
• A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
• A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
• Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
• A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
• Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
• A Study of Tor Kinase Inhibitor in Advanced Tumors
• Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
• Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors
• Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
• A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
• Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
• A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
• Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
• Administration of BIIB028 to Subjects With Solid Tumors
• A Phase 1 Dose Escalation Study of IPI-493
• F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
• A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
• Natural Killer Cells and Bortezomib to Treat Cancer
• American Ginseng in Treating Patients With Fatigue Caused by Cancer
• AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
• A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
• Solid Tumors Using Ixabepilone and Dasatinib
• Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
• Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
• Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
• Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
• A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
• Safety Study of GPX-150 in Patients With Solid Tumors
• Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
• Study of Rapamycin Plus Ketoconazole in Advanced Cancers
• A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
• Rapamycin in Advanced Cancers
• PTC299 for Treatment of Advanced Cancer
• A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
• Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
• Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
• Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
• A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
• Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
• Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
• Study of Capecitabine In Patients With Solid Tumors
• Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
• Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
• Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
• Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
• Safety Study of CALAA-01 to Treat Solid Tumor Cancers
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
• Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
• Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
• Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
• A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
• Study of Denosumab in Subjects With Giant Cell Tumor of Bone
• Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
• Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
• AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
• Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
• A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.
• A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
• A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
• Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
• A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
• INCB018424 in Patients With Advanced Hematologic Malignancies
• A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
• Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
• Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
• Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
• Rapamycin Plus Bevacizumab in Advanced Cancers
• Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
• Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
• A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
• A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
• Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
• Study of GemOx and Vandetanib in Advanced Solid Malignancy
• Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
• Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
• Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
• Evaluation of KX2-391 in Patients With Advanced Malignancies
• A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
• An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
• Phase 1 Study of MKC-1 in Patients With Advanced Cancer
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
• A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
• Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
• A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
• A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
• A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
• Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
• Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
• Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
• Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
• Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
• Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
• A Study of ARRY-334543 in Patients With Advanced Cancer
• Study of AZD8931 in Patients With Advanced Solid Malignancies
• Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
• Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
• ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
• CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
• A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
• Oral NRX 194204 in Patients With Refractory Malignancies
• Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
• Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
• Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
• A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
• Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
• Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
• Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
• A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
• Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
• Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
• PR104 and G-CSF in Treating Patients With Solid Tumors
• A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
• PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
• Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
• Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
• Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
• Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
• Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors
• GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
• Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
• Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors
• Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
• S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
• Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
• Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
• A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
• Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
• MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
• A Phase I Trial of ZIO-101 in Solid Tumors
• Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
• Phase I Study in Advanced Solid Tumors
• Phase I Study of Indibulin in Patients With Solid Tumors
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
• Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)
• Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
• One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
• Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
• Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
• Open Label, Dose Escalation Phase I Study of AZD2281
• Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
• QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
• Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
• A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
• Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
• A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
• Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
• LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
• Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
• Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
• Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
• LBH589 and Gemcitabine in the Treatment of Solid Tumors
• Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
• A Phase I Study of G3139 Subcutaneous in Solid Tumors
• Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
• Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
• Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
• First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
• Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
• Concentration of Ertapenem in Colorectal Tissue
• Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA
• Valproic Acid and Bevacizumab in Patients With Advanced Cancer
• RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
• Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
• An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
• Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
• Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
• Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
• Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors
• Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
• Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
• MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
• Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
• Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
• High-Dose Methotrexate in Treating Young Patients With Solid Tumors
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
• Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
• RTA 744 Injection in Patients With Leptomeningeal Disease
• Doxercalciferol in Recurrent Pediatric Solid Tumors
• Phase I Trial of ZIO-101 in Patients With Solid Tumors
• RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
• Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
• Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
• Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
• Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
• Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
• Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
• A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
• A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
• Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
• Phase I Chinese PK
• Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
• Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
• A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
• Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
• A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
• Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
• AZD1152 in Patients With Advanced Solid Malignancies-Study 1
• AZD1152 in Patients With Advanced Solid Malignancies-Study 3
• Phase I Study of Patupilone and RAD001
• Azacytidine and Valproic Acid in Patients With Advanced Cancers
• MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
• Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
• Olanzapine in Patients With Advanced Cancer and Weight Loss
• Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
• Effects of Mirtazapine on Appetite in Advanced Cancer Patients
• A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)
• Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
• Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
• Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
• A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
• A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT
• Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
• A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
• Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
• Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
• Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
• Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
• A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
• Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
• Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
• Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
• Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
• The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
• Study of Cobimetinib in Participants With Solid Tumors
• Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
• Trial of Dasatinib in Advanced Sarcomas
• AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
• Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
• Study of XL418 in Adults With Solid Tumors
• PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
• Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
• Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
• AZD8330 First Time in Man in Patients With Advanced Malignancies
• Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
• Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
• Alemtuzumab and Pentostatin In T-cell Neoplasms
• Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
• Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors
• Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
• Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
• Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
• Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
• An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
• Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
• Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
• Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
• Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
• Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
• Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
• VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
• A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
• Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
• Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
• Study of Atiprimod Treatment for Patients With Advanced Cancer
• Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
• Gemcitabine and Dasatinib in Advanced Solid Tumors
• A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
• Bevacizumab and Bortezomib in Patients With Advanced Malignancy
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
• Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
• Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
• Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
• Voraxaze for Delayed Methotrexate Clearance
• Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
• Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
• Methylphenidate and a Nursing Telephone Intervention for Fatigue
• Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
• Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
• Parenteral Hydration in Advanced Cancer Patients
• A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer
• Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
• A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
• Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
• A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
• A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
• Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
• A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
• Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
• A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
• XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
• Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
• Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases
• Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
• Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
• Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
• Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
• Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
• Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
• Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
• Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
• Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
• Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
• A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
• Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
• Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
• Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
• ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
• Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
• A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
• A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
• A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
• A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
• Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
• Darbepoetin Alfa With or Without Intravenous (IV) Iron
• Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors
• Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
• Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
• AS703569 Phase I in Patients With Solid Tumours
• Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
• A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
• Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
• Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
• Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
• 3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
• Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
• Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
• Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
• Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
• PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
• Sunitinib in Treating Young Patients With Refractory Solid Tumors
• Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
• Study of XIAP Antisense for Advanced Cancers
• Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
• Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
• Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
• Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
• Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
• A Trial for Patients With Advanced/Recurrent Endometrial Cancer
• Dose Escalation Study of SH U04722 in Solid Tumors
• Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction
• AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
• Phase I Study of Nimotuzumab in Solid Tumours
• AFP464 in Treating Patients With Advanced Solid Tumors
• Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)
• One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
• Trial of PTK787/ZK 222584 Plus Paclitaxel
• AEG35156 and Docetaxel in Treating Patients With Solid Tumors
• Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
• A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
• PR-104 in Treating Patients With Advanced Solid Tumors
• Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
• Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
• Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
• AZD1152 in Patients With Advanced Solid Malignancies
• Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
• Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
• Ixabepilone in Treating Young Patients With Refractory Solid Tumors
• Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
• A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
• EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
• Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
• Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
• Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
• Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
• AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
• Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
• Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
• Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
• Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
• Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
• Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors
• Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
• Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
• ARQ 197 in Subjects With Metastatic Solid Tumors
• S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
• Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
• Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
• Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
• A Randomized Study of Sulindac in Oral Premalignant Lesions
• Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
• Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
• Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
• Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
• CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
• Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
• Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
• Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
• Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
• Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
• A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
• Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
• An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
• A Study of ARRY-334543 in Patients With Advanced Cancer
• A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
• Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors
• Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
• Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
• Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
• Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
• The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer
• Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
• Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
• Study of ADH-1 Given Intravenously to Patients With Solid Tumors
• A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
• A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
• A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
• Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor
• Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
• Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
• Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
• Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
• A Study of MLN8054 in Patients With Advanced Solid Tumors
• 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
• Safety Study of 2DG With Stereotactic Radiosurgery
• Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II
• Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
• Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
• Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
• Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
• Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
• Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
• Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
• G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
• A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
• Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
• Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
• Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
• Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
• Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
• An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
• ONO-7436 Phase II Study in Japan
• Optimisation and Performance of Reduced Preparation CT Colography
• An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
• Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
• Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
• A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
• MAD Refractory: Solid Tumor QD w/o Break
• Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
• Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
• Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
• Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
• Hypertonic Saline 75% vs Mannitol 20%
• Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
• Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
• Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
• Study Evaluating TTI-237 in Advanced Malignant Solid Tumors
• Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies
• An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
• A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
• A Trial for Patients With Advanced/Recurrent Cervical Cancer
• A Trial for Patients With Gestational Trophoblastic Disease
• Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
• Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
• Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
• Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
• Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
• Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
• Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
• Allogeneic Transplantation From Related Haploidentical Donors
• Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
• High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
• Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
• A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia
• Safety Study of S-CKD602 in Patients With Advanced Malignancies
• Stem Cell Transplantation for Hematological Malignancies
• Dextromethorphan in Treating Patients With Fatigue Caused by Cancer
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
• SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
• A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
• Study of Dasatinib in Patients With Advanced Solid Tumors
• Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
• A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
• Stem Cell Transplantation for Patients With Hematologic Malignancies
• Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas
• Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
• Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
• AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
• Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)
• Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
• Determination of Carboplatin's Optimal Plasmatic Exposure
• Irinotecan Versus Only Best Supportive Care for Gastric Cancer
• Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
• Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
• Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
• Docetaxel and Capecitabine in Advanced Gastric Cancer
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
• Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
• Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
• Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
• SB-743921 In Patients With Solid Tumors
• AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
• Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
• A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
• Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
• MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
• Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
• A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Solid Tumors (0683-029)(COMPLETED)
• Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
• Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
• An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
• Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
• SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
• Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
• 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
• Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
• Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
• Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
• A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
• 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
• Study of Oral AEE788 in Adults With Advanced Cancer
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
• A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
• Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
• Study of TPI 287 in Patients With Advanced Malignancies
• Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
• Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
• Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
• Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
• Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
• OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206
• Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
• Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
• Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
• Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• Campath-1H + FK506 and Methylprednisolone for GVHD
• Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
• Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
• Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
• Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
• Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
• Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
• Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
• SJG-136 in Treating Patients With Advanced Solid Tumors
• Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
• A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
• Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors
• Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
• A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
• Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
• Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
• A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
• A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
• Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
• CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
• The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
• Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
• BMS-599626 in Patients With Advanced Solid Malignancies
• Study of NS-9 in Patients With Liver Metastases
• Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
• Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
• Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
• AZD5438 in Patients With Advanced Solid Malignancies
• Study Evaluating MST-997 in Advanced Malignant Solid Tumors
• STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
• Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
• Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
• Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
• Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
• A Study of ARRY-142886 in Patients With Advanced Cancer
• Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
• Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
• Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
• Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
• Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
• Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
• Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
• Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
• Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
• Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
• Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
• Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
• Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
• Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
• GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
• TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
• DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
• Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
• Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
• Study Evaluating EKB-569 in Advanced Colorectal Cancer
• Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
• Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
• Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
• Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
• Study of E7389 in Patients With Advanced Solid Tumors
• Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
• A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
• Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
• Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
• Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
• Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
• Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• Study Evaluating MAC-321 in Colorectal Cancer
• Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
• Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
• Study of Karenitecin (BNP1350) in Patients With Brain Tumors
• Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
• Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
• Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
• High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
• GW786034 in Treating Patients With Advanced Solid Tumors
• Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
• Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
• Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
• A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
• A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
• Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
• Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
• Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
• Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
• Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
• Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
• A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
• A Study of Trabectedin in Patients With Advanced Ovarian Cancer
• Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
• Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
• Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
• Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
• Study of ABT-751 in Patients With Refractory Hematologic Malignancies
• Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
• UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
• Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
• E7389 in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
• Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
• ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
• A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
• Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
• Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
• Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
• BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
• Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
• IUdR/BUdR Cell Cycle Labelling
• Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
• Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
• Gefitinib in Treating Children With Refractory Solid Tumors
• Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer
• Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
• Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
• Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
• Anemia in Patients With a Non-Myeloid Malignancy
• Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
• Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
• Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
• For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
• ABT-751 in Treating Young Patients With Refractory Solid Tumors
• Arsenic Trioxide in Treating Men With Germ Cell Cancer
• UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors
• Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery
• Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
• Chemotherapy Related Anemia
• EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
• EPO906 Therapy in Patients With Advanced Colorectal Cancer
• A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
• A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
• This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
• A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
• Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
• Comparing 3 Schedules of Alimta Plus Gemzar
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
• Study of Noni in Cancer Patients
• S-3304 in Treating Patients With Advanced Solid Tumors
• A Phase 1 Study of S-3304 in Patients With Solid Tumors
• This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
• Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
• S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
• 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
• BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
• A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
• Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
• Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
• Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
• Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
• R115777 in Treating Patients With Advanced Solid Tumors
• Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
• Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
• Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
• 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
• SU6668 in Treating Patients With Advanced Solid Tumors
• Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
• PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
• Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
• Phenoxodiol in Treating Patients With Refractory Solid Tumors
• EMD 121974 in Treating Patients With Advanced Solid Tumors
• Bortezomib in Treating Children With Advanced Solid Tumors
• Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
• Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
• Vaccine Therapy in Treating Patients With Multiple Myeloma
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
• Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
• KRN5500 in Treating Patients With Solid Tumors
• PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
• S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
• Benzoylphenylurea in Treating Patients With Advanced Solid Tumors
• Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
• Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
• Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
• 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
• Combination Chemotherapy in Treating Patients With Solid Tumors
• Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
• Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
• Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
• Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
• Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
• Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
• Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
• Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
• UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
• Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
• LY293111 in Treating Patients With Advanced Solid Tumors
• Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
• Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
• BMS-214662 in Treating Patients With Advanced Solid Tumors
• Paclitaxel in Treating Patients With Ovarian Stromal Cancer
• SU5416 and Carboplatin to Treat Ovarian Cancer
• Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
• Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
• Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors
• CP-609,754 in Treating Patients With Advanced Solid Tumors
• Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
• SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
• SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
• BMS-214662 in Treating Patients With Solid Tumors
• Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
• Oxaliplatin in Treating Children With Advanced Solid Tumors
• Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
• Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma
• Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia
• Bone Marrow Transplant in Treating Patients With Hematologic Cancers
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
• Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
• Gemcitabine in Treating Children With Refractory Solid Tumors
• Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
• Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
• Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
• Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria
• Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors
• Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
• Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
• MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
• Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
• Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
• Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
• Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
• DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
• Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors
• Irinotecan in Treating Children With Refractory Solid Tumors
• PNU 166148 in Treating Patients With Metastatic Solid Tumors
• Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
• Irinotecan in Treating Patients With Advanced Solid Tumors
• Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
• KRN7000 in Treating Patients With Solid Tumors
• MEN-10755 in Treating Patients With Solid Tumors
• E7070 in Treating Patients With Solid Tumors
• BIBX 1382 in Treating Patients With Solid Tumors
• CHS 828 in Treating Patients With Solid Tumors
• E7070 in Treating Patients With Solid Tumors
• Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
• Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
• Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
• Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
• Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
• Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
• Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
• Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
• O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
• Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Chemotherapy in Treating Patients With Advanced Solid Tumors
• CCI-779 in Treating Patients With Advanced Solid Tumors
• Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
• Chemotherapy in Treating Patients With Advanced Solid Tumors
• Chemotherapy in Treating Patients With Solid Tumors
• Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
• High-dose ICE With Amifostine
• Combination Chemotherapy in Treating Men With Germ Cell Cancer
• Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
• Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
• Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
• Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
• Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
• SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
• Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
• High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
• Paclitaxel in Treating Women With Recurrent Solid Tumors
• Fenretinide in Treating Patients With Cervical Neoplasia
• Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
• MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors
• Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
• Combination Chemotherapy in Treating Children With Progressive Brain Tumors
• Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
• Penclomedine in Treating Patients With Advanced Solid Tumors
• Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
• Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
• Melphalan in Patients With Neoplastic Meningitis
• Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
• Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
• Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
• Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
• Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
• Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
• Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors
• Stem Cell Transplantation for Metastatic Solid Tumors
• Oxaliplatin in Cancer Patients With Impaired Kidney Function
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
• A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
• A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
• A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
• Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
• A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
• A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
• Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
• A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
• Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
• A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
• Gene Therapy for the Treatment of Brain Tumors
• A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
• Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
• Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
• Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
• Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
• Women's Health Initiative (WHI)